Final Agenda
Day 1 | Day 2 | Day 3 | Download Brochure
Recommended Pre-Conference Short Courses *
(SC5) Early Drug Development and First-in-Human Dose Regimen
*Separate Registration Required.
7:00 am Registration and Morning Coffee
8:00 Plenary Keynotes - Details
9:40 Grand Opening Refreshment Break in the Exhibit Hall
11:00 Chairperson’s Opening Remarks: James Gulley, NCI/NIH
11:10 Sipuleucel-T Immunotherapy for Advanced Prostate Cancer
David L. Urdal, Ph.D., Chief Scientific Officer, Dendreon Corporation
Will describe the clinical efficacy and safety data supporting FDA approval of the first autologous cellular immunotherapy approved for the treatment of cancer. Data on immune response, product potency, and correlation of potency measures with clinical outcomes will be described.
11:40 Cancer Vaccines: New Paradigm in Changing Cancer to a Chronic Disease
Helen Sabzevari, Ph.D., Global Head, Oncology-Immunotherapy, EMD-Serono, Inc.
12:10 pm Ipilimumab Development: Contribution to a New Immunotheray Paradigm
Axel Hoos, M.D., Ph.D., Medical Lead, Immunology/Oncology, Bristol-Myers Squibb
Ipilimumab development has contributed valuable lessons to the evolution of a new development paradigm for cancer immunotherapies as spearheaded by the Cancer Immunotherapy Consortium. This new paradigm encompasses new tools and development principles for immuno-oncology. It offers a better defined path for development of new therapies in this space.
12:40 Luncheon Presentations or Lunch on Your Own
1:45 Dessert in the Exhibit Hall
2:20 HN1: a Novel Human Monoclonal Antibody Targeting Mesothelin for Cancer Therapy
Mitchell Ho, Ph.D., Head, Antibody Therapy Unit, LMB, National Cancer Institute, National Institutes of Health
We recently generated HN1, a fully human IgG, that binds mesothelin with high affinity. The HN1 epitope is different from that of SS1, a mouse Fv used to develop an immunotoxin (SS1P) and a chimeric antibody (MORAb-009) that are currently in clinical trials. HN1 binds strongly to cell surface-associated mesothelin on mesothelioma, ovarian cancer, lung adenocarcinoma and pancreatic cancer cells. HN1 kills cancer cells with very strong antibody-dependent cell-mediated cytotoxicity and has potential for mesothelin-expressing cancer treatment.
2:50 Initial Experience With Autologous Heat Shock Protein Vaccine for Brain Tumor Patients
Andrew T. Parsa, M.D., Ph.D., Associate Professor in Residence of Neurological Surgery, Reza & Georgianna Khatib Endowed Chair in Skull Based Tumor Surgery; Principal Investigator, Brain Tumor Research Center, University of California, San Francisco
3:20 Genomics-Guided Personalized Immunotherapy of Human Cancers: Rationale & Challenges
Pramod Srivastava, Ph.D., Director, Center for Cancer & Infectious Disease, University of Connecticut
High throughput DNA sequencing, and sophisticated informatics tools provide new opportunities for immunotherapy of human cancer. The scientific and clinical rationale for these opportunities, as well as the novel logistical and regulatory challenges expected of them, shall be discussed.
3:50 Sponsored Presentations
4:20 Reception in the Exhibit Hall (Sponsorship Available)
5:20 Breakout Discussions in the Exhibit Hall
Concurrent Problem Solving Break-Out Sessions are interactive, problem solving discussions hosted by a moderator to discuss a topic in depth. The discussions are open to all attendees, sponsors, exhibitors, and speakers and provide a forum for discussing key issues and meeting potential partners. Please pick a topic of your choice and join in.
Imaging as a Co-Developed Diagnostic to Meet FDA Standards
Rikki N. Waterhouse, Ph.D., Senior Group Leader, Abbott
Picking Perfect Patients
James L. Gulley, M.D., Ph.D., F.A.C.P., Director, Clinical Trials Group, Tumor Immunology and Biology, NCI/NIH
CTC Methods Development Strategies for New Biomarkers
Lihua Wang, Senior Scientist, Pharmacodynamic Assay Development Section, Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Directorate, SAIC-Frederick, Inc., NCI-Frederick
6:20 Close of Day
Day 1 | Day 2 | Day 3 | Download Brochure